Erlotinib for Liver Cancer Prevention

(ECHO-B Trial)

Overseen By Lisa Quirk, MS, MPH

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: University of Texas Southwestern Medical Center

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

What You Need to Know Before You Apply

What is the purpose of this trial?

This phase II randomized placebo-controlled trial studies low-dose erlotinib treatment to assess its efficacy and safety to prevent development of hepatocellular carcinoma in patients with advanced liver fibrosis or cirrhosis.

Who Is on the Research Team?

Yujin Hoshida

Principal Investigator

UT Southwestern

Amit Singal, MD, MS

Principal Investigator

UT Southwestern

Are You a Good Fit for This Trial?

This trial is for individuals with advanced liver fibrosis or cirrhosis who have not developed hepatocellular carcinoma (liver cancer). Participants must be in stable condition without active liver failure, have good blood, liver, and kidney function, and be able to perform daily activities without significant assistance.

Inclusion Criteria

I have been diagnosed with cirrhosis.

My liver is functioning properly.

I have never had liver cancer.

What Are the Treatments Tested in This Trial?

Interventions

• Erlotinib Hydrochloride

Trial Overview The study is testing the effectiveness of a low-dose erlotinib hydrochloride treatment compared to a placebo in preventing liver cancer. It's a phase II trial where participants are randomly assigned to receive either the medication or an inactive substance.

How Is the Trial Designed?

Group I: Erlotinib treatment Experimental Treatment 1 Intervention

Group II: Placebo Placebo Group 1 Intervention

Who Is Running the Clinical Trial?

University of Texas Southwestern Medical Center

Lead Sponsor

Trials

1,102

Recruited

1,077,000+

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+